Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

BioHarvest Sciences to begin human clinical study with multiple sclerosis-related optic neuritis

BioHarvest Sciences CEO Ilan Sobel joined Proactive's Steve Darling to share news the company has agreed to a collaboration with the International Neurorehabilitation Institute in Maryland to perform a clinical trial to assess the capacity of the company’s red grape cell (RGC) composition to promote eye health.

RGC is produced using BioHarvest's Botanical-Synthesis technology.

Sobel told Proactive the study will be an open-label clinical study to evaluate the impact of RGC on multiple sclerosis-related optic neuritis driven by inflammation. The Multiple Sclerosis Foundation estimates more than 1 million people in the US and about 2.5 million people worldwide have been diagnosed with MS.

Contact Details

Proactive Investors Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.